Article
Protecting New Investments in Old Drugs
Authors
-
- Name
- Person title
- Senior Principal
FDLI Update Magazine, 2009, Issue 2
By: Terry G. Mahn
In an earlier article, the author discussed the shift taking place since the 2003 Orange Book reforms with pioneer drug companies looking for new ways to protect old drugs. A creative approach followed by some pioneers has been to patent new drug features that would appear on drug labels in the form of patent protected language that generic manufacturers are then either forced to infringe, await expiration or seek Food and Drug Administration (FDA) permission to "carve out."
The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.